Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMXT 1501 and DFMO + SOC in Advanced Solid Tumors
NCT07287917Phase 2Recruiting
- Sponsor
- Aminex Therapeutics
- Start
- Jan 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AMXT-1501, eflornithine in breast cancer, melanoma, sponsored by Aminex Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
AMXT-1501eflornithine
03
Conditions
breast cancermelanoma
Beyond the preview
Go deeper on NCT07287917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07287917.